General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
A dental materials maker in Bari Brahmana, Jammu, reported quarterly sales of ₹19.44 crore for the June 2026 quarter — up 23.7% over the same quarter last year, and the highest quarterly sales figure in the ten quarters the company has printed. Operating profit came in at ₹6.89 crore, net profit at ₹5.78 crore, EPS at ₹4.82.
The borrowings line on this balance sheet has been blank since March 2023, which in a country where “almost debt free” is treated as a personality trait puts the company in rare company. Interest cost in the quarterly statement is a row that exists purely out of formatting courtesy.
Meanwhile the inventory days figure reached 235 in FY26, up from 208. Somewhere in a 60,000 sq ft facility, root canal sealant is aging like it has ambitions in the wine trade.
The quarter also carried a one-off: management disclosed that implementing the new Labour Codes from April 1, 2026 increased employee benefit expense for the period by ₹27.80 lakh. Employee cost for the quarter was ₹338.23 lakh on a standalone basis.
Other Income for the quarter: ₹1.33 crore, against operating profit of ₹6.89 crore. The company holds ₹72.65 crore of cash and bank balances as of March 2026, so the Other Income line has raw material to work with.
Promoter holding has been 73.60% for twelve straight quarters, unmoved, unbothered, to the second decimal place.
2. Introduction
The company was incorporated in 1999 (the investor presentation dates the establishment to 1999; Screener’s About section says 2000), and by its own account began life in a 200 square foot manufacturing facility. That is roughly the footprint of a generous studio apartment. It now operates from a 60,000 sq ft unit in the Export Promotion Industrial Park at Bari Brahmana, Jammu, with an in-house R&D lab attached.
It listed on the BSE SME platform in 2021. The strategic timeline in the FY26 presentation reads like a company that discovered geography and could not stop: Axiodent Inc. established in the USA in 2024, MoUs signed in 2025 with the Indian Dental Association for clinical education and with IIT Kanpur for biomaterials and biomedical devices, Prevest Gulf LLC established in the UAE, and a capital infusion into that Gulf subsidiary in FY26. In February 2025 the company disclosed an investment of $50,000 into Axiodent Inc.
The group now consolidates four entities: the holding company, Denvisio Biomed Limited (incorporated May 2023), Axiodent Inc., and Prevest Denpro Gulf General Trading LLC. The auditors noted that the two foreign subsidiaries together contributed revenue of ₹5.71 lakh and a net loss after tax of ₹16.81 lakh before consolidation adjustments in the June 2026 quarter — numbers that would round to zero on most spreadsheets and which management represented as not material to the group.
On the certifications front the company lists ISO 13485-2016, ISO 22716, an EC certificate, USFDA, Saudi FDA and MDSAP. A dental materials manufacturer accumulates regulatory approvals the way other companies accumulate subsidiaries, and this one does both.
For FY26 the company declared a final dividend of ₹1.00 per share on a face value of ₹10 — a 10% dividend, the same 10% announced as a maiden dividend back in 2023, which suggests a payout policy carved into something quite hard. The dividend amount has been ₹1.2 crore in each of the last four financial years.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
They make the stuff a dentist puts into your mouth after removing the bits that offended them.
The portfolio runs past 100 products across restorative materials (cavity filling solutions, sold under Crysta Restorative and Fusion Restorative Kits), endodontic solutions for root canals (Endoseal), preventive care for post-extraction and decay prevention (Alvocure, Fusion Flo Combo Kit), orthodontic adhesives for braces and aligners, and impression materials and cements (Crysta Luting, Fusion I-Seal). Brands include Micron, Actino, Fusion Flo, Activa and Enamel Pro. This is a company that has named a product Endoseal MICRON SUPERIOR, which is what happens when the marketing department and the R&D department are on speaking terms.
Two new categories opened in FY26. Digital dentistry, sold under the Omni brand — 3D printing resins and, since last November, actual 3D printers. And disinfectants, which management describes as having begun commercial scale-up during the year.
The distribution machinery is the part that looks disproportionate to the ₹71.66 crore of FY26 revenue. Exports go to 90-plus countries, supported by 145 dealers in India and 120 overseas business partners. Screener’s extracted operating data shows dealers in India jumping from 60 to 145 in the latest year and overseas agents from 90 to 120. Somebody has been very busy signing people up.
Capacity utilisation on the core traditional lines runs at roughly 67–68%, and management stated that at full utilisation, turnover would be around ₹125 crore. The newer lines — digital dentistry, resins, disinfectants, oral health — are running at approximately 18–20% utilisation. A factory operating at one-fifth of its capacity is a factory with a great deal of unused floor and a lot of opinions about the future.
Domestic revenue share was 42.10% of revenue from operations in the latest year for which Screener extracted it, up from 41.55%. R&D expenditure was extracted at 18.06% of turnover — a figure that, for a company making cement that lives inside teeth,
